Navigation Links
Epeius Biotechnologies Corporation Expands its Rexin-G Production Facilities in Southern California
Date:2/18/2010

SAN MARINO, Calif., Feb. 18 /PRNewswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) announces the completion of the design engineering and construction phase of a state-of-the-art Vector Production Unit (VPU) for the commercial manufacturing of its advanced targeted genetic medicines. In accordance with an FDA Critical Path initiative, which encourages innovation and the implementation of new technological advances in GMP, CMC, aseptic processing, and quality control, the Epeius VPU is poised to launch the large-scale production of targeted genetic medicine into the 21st century. By combining the most advanced modular clean-room engineering specifications with space-age materials, aseptic processes, and robotic operations, the stunning new facility exemplifies a new level of cleanliness, efficiency, productivity, and cost-effectiveness, as well as product quality control, all by design.

Housed in a spacious NASA-style hangar and seated onto an expansive seamless epoxy floor, the elegant stainless steel and glass facility is pleasing to the eye, both inside and out, as large windows and walls of plate glass rise to form corridors with twelve-foot ceilings. Equipped with clean-room air handling systems derived from the high-tech industry, the impeccable cleanliness of the enveloped interior is further maintained by batteries of UV-lights embedded within the integral ductwork. The outstanding level of high-tech innovation embodied in the Epeius VPU is hardly surprising, considering that systems engineers from Terra Universal critical environment solutions worked closely with Epeius scientists on the plant's design features.

By streamlining material flow, personnel tasks, and bioprocessing operations, while reducing overall footprint and manual labor, the modular, robotic VPU provides an optimization of single-use technologies and the decoupling of solution preparation from the process, thereby providing increased operating efficiencies, large economies-of-scale, and enhanced quality assurance.

This modular, robotic VPU serves as a flagship facility that meets and exceeds the challenges of operating economy, process optimization, and operational excellence, as it extends these concepts to the bio-manufacturing industry of the 21st century. From its inception as an academic startup enterprise -- incubated at The University of Southern California School of Medicine -- to its emergence as a global leader in the field of targeted genetic medicine, Epeius Biotechnologies has advanced the science of molecular genetics from the bench to the bedside in a manner that is unprecedented in modern times. By working closely with acknowledged leaders in the fields of molecular biotechnology, biopharmaceutical manufacturing, and clean-room fabrication, Epeius Biotechnologies is striving to make the promise and potential of targeted genetic medicine more abundant and affordable for cancer patients worldwide.

About Epeius Biotechnologies:

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its leading oncology products and its tumor-targeted delivery systems. Visit us at www.epeiusbiotech.com.

*(PHOTO: Send2Press.com/mediaboom/10-0219-EpeiusBio_300dpi.jpg)

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com

SOURCE Epeius Biotechnologies

Back to top

RELATED LINKS
http://www.epeiusbiotech.com

'/>"/>

SOURCE Epeius Biotechnologies
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
2. Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo
3. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
4. FDA Grants Epeius Biotechnologies Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
5. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
6. Targeting Metastatic Cancer From the Inside: Epeius Biotech Reveals a New Generation of Tools for Medical Gene Delivery
7. Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
8. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
9. Epeius Biotechnologies to Partner at BIO Investor Forum
10. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
11. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... Park Systems , ... AFM Luncheon for all SPIE attendees and Park customers on Feb. ... block from the San Jose Convention Center. The luncheon will feature a talk ...
(Date:2/22/2017)... -- Scientists propose in Nature blocking a ... and maybe other lysosomal storage diseases as a possible ... therapies. An international research team led by ... included investigators from the University of Lübeck in ... The study was conducted in mouse models of lysosomal ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... of precision treatments for neurodegenerative diseases, today announced it has issued a scientific ... This is one of a series of commentaries from ProMIS’s scientific team offering ...
(Date:2/22/2017)... ... February 22, 2017 , ... LabRoots , the ... from around the world, is pleased to announce the launch of a new scholarship ... mathematics (STEM) fields. , This merit-based scholarship is open to all high school seniors, ...
Breaking Biology Technology:
(Date:2/13/2017)... , Feb. 13, 2017 Former 9/11 ... Senate Judiciary Committee, Janice Kephart of Identity ... President Donald Trump,s "Executive Order: Protecting the ... (Jan. 27, 2017):  "As President Trump,s ,Travel ... Circuit has now essentially banned the travel ban, it ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
(Date:2/7/2017)... , February 7, 2017 Ipsidy ... Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") a ... transaction processing services, is pleased to announce the following ... Effective January 31, 2017, Philip D. ... Directors, CEO and President.  An experienced payment industry professional ...
Breaking Biology News(10 mins):